Practicing radiologists, radiation oncologists, and trainees were surveyed regarding the current state of subspecialization in practice and in training curricula. The authors present the results of these surveys, establish trends compared with previous survey data, and compare the plans of trainees with current postgraduate practice. Subspecialization is increasing in both radiology and radiation oncology. There remain substantial numbers of practitioners who perform work they deem "general" in nature. The authors also present a method to more accurately measure subspecialization and workload.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jacr.2008.11.025 | DOI Listing |
Ann Surg Oncol
January 2025
Department of Radiology, University of Washington, Seattle, WA, USA.
Background: Ductal carcinoma in situ (DCIS) is overtreated, in part because of inability to predict which DCIS cases diagnosed at core needle biopsy (CNB) will be upstaged at excision. This study aimed to determine whether quantitative magnetic resonance imaging (MRI) features can identify DCIS at risk of upstaging to invasive cancer.
Methods: This prospective observational clinical trial analyzed women with a diagnosis of DCIS on CNB.
Radiology
January 2025
Department of Radiation Oncology, IU Health Cancer Pavilion-University Hospital, 535 Barnhill Dr, RT-041, Indianapolis, IN 46202.
Radiology
January 2025
From the Rush University Medical Center, 1620 W Harrison St, Chicago, IL 60612 (B.H.M., F.G., H.W.A.A., S.G.D., C.D.D., M.A.M.); and University of Texas Health Science Center, Houston, Tex (X.R.Z.).
A 38-year-old previously healthy male patient presented with left-sided facial pain over the prior 5 weeks. He first noticed the pain while washing and applying pressure to his face. The pain was described as shock-like, sharp and shooting, and radiating along the left cheek and temple.
View Article and Find Full Text PDFJ Hepatocell Carcinoma
January 2025
Department of Oncology, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, Jiangxi, People's Republic of China.
Purpose: The optimal timing for combining radiotherapy with immunotherapy in patients with hepatocellular carcinoma (HCC) remains uncertain and affects treatment efficacy and patient outcomes. This study aimed to evaluate and compare the efficacy and treatment-related adverse events (TRAEs) of synchronously administered radiotherapy and programmed cell death protein (PD)-1 inhibitors and sequential administration in patients with HCC.
Patients And Methods: We retrospectively enrolled 67 patients with HCC who were undergoing liver radiotherapy and PD-1 inhibitor therapy at two medical centers between July 2017 and April 2023.
Small Methods
January 2025
Division of Thoracic Tumor Multimodality Treatment, Department of Radiation Oncology, Department of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging, Cancer Center, Breast Center, Institute of Breast Health Medicine, Laboratory of Clinical Cell Therapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Non-small cell lung cancer (NSCLC) has a strikingly high incidence rate globally. Although immunotherapy brings a great breakthrough in its clinical treatment of NSCLC, significant challenges still need to be overcome. The development of novel multi-functional nanomedicines in the realm of tumor immunotherapy offers promising opportunities for NSCLC patients, as nanomedicines exhibit significant advantages, including specific targeting of tumor cells, improved drug bioavailability, reduced systemic toxicity, and overcoming of immune resistance.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!